PODCAST: A Biotech Buyout, and an Influencer Uprising

Illustration of a money burning biotech lab

By Doug Young & Rene Vanguestaine

AstraZeneca has offered to buy money-losing Gracell Biotech for up to $1.2 billion, in a first-of-its kind M&A for a Chinese drug startup. Will China approve the deal? And e-commerce company East Buy’s CEO gets sacked under pressure from its top online salesman. How much power do such influencers wield at Chinese internet companies?

About China Inc

China Inc by Bamboo Works discusses the latest developments on Chinese companies listed in Hong Kong and the United States to drive informed decision-making for investors and others interested in this dynamic group of companies.

Subscribe to China Inc on your favorite app:

Apple Podcasts Spotify Google Podcasts

,
, , , , , , , ,

Related Articles

RELATED ARTICLES

  1. This Chinese cell therapy specialist, whose core product is still in phase 1 trials, will avoid future cash flow difficulties by selling itself to the European giant.
    With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
    GRCL.US
  2. FAST NEWS: Gracell shareholders approve merger with AstraZeneca
    GRCL.US
  3. CHINA BULLETIN: China-India Tensions Flare with New Arrests
  4. CHINA BULLETIN: PMI Readings Signal Strong End to 2023
  5. Cash-strapped Viva Biotech sells stake and plans spinoff
    1873.HK
  6. AstraZeneca pays hefty price for Chinese weight-loss drug
    AZN.US
  7. ProfoundBio discovers the joys of having a wealthy owner
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo File-alt

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

Recent Articles

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing.

Sunho Biologics gets green light for downsized IPO

The loss-making developer of cancer immunotherapies raised just enough financing last year to cross the valuation threshold for a Hong Kong listing Key Takeaways: Sunho Biologics has no revenue or…